ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Biomarkers"

  • Abstract Number: 364 • 2014 ACR/ARHP Annual Meeting

    In Early Rheumatoid Arthritis, the Multi-Biomarker Disease Activity Score at Different Time-Points Is Predictive of Subsequent Radiographic Progression

    Karen Hambardzumyan1, R.J. Bolce2, Saedis Saevarsdottir*3, Kristina Forslind4, Ingemar F. Petersson5, Pierre Geborek6, Eric H. Sasso2, David Chernoff2, Scott Cruickshank7 and Ronald F. van Vollenhoven8, 1ClinTRID, the Karolinska Institute, Stockholm, Sweden, 2Crescendo Bioscience Inc., South San Francisco, CA, 3Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 4Department of Medicine, Karolinska Institute, Stockholm, Sweden, 5Lund University, Lund, Sweden, 6Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, 7Scott Cruickshank and Associates, Inc., Santa Barbara, CA, 8Unit for clinical therapy research (ClinTrid), Karolinska Institute, Stockholm, Sweden

    Background/Purpose The prediction of radiographic progression in early rheumatoid arthritis (eRA) patients is important for optimal treatment. We previously demonstrated that a multi-biomarker disease activity…
  • Abstract Number: 2795 • 2014 ACR/ARHP Annual Meeting

    Blockade of IL-6R Signaling by Sarilumab Suppressed Circulating Markers of Bone Resorption and Synovial Damage in Rheumatoid Arthritis Patients from a Phase 3, Randomized, Double-Blind, Placebo-Controlled, International Study

    Anita Boyapati1, Jérôme Msihid2, Emmanuelle Cousin3, Ling Cai4, Janet van Adelsberg1, Jennifer D Hamilton1, Neil Graham5, Tanya Momtahen6 and Stefano Fiore7, 1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 2Sanofi R&D, France, Chilly-Mazarin, NJ, France, 3Sanofi R&D, France, Chilly-Mazarin, France, 4Sanofi R&D, China, Beijing, China, 5Program Direction, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 6Sanofi, Bridgewater, NJ, 7Distinct Project Unit, Sanofi, Bridgewater, NJ

    Background/Purpose Rheumatoid arthritis (RA) patients develop bone and joint damage due to chronic inflammation mediated by critical cytokines, eg, IL-6. Pre-clinical studies have implicated IL-6…
  • Abstract Number: 1754 • 2014 ACR/ARHP Annual Meeting

    Peripheral CD5+ b-Cells in ANCA-Associated Vasculitis

    Sebastian Unizony1, Noha Lim2, Vincent Carey3, Deborah J. Phippard2, Nadia Tchao2, Eli M. Miloslavsky4, Peter A. Merkel5, Paul Monach6, William St. Clair7, Robert F. Spiera8, Adam Asare2, Philip Seo9, Carol A. Langford10, Gary S. Hoffman11, Cees Kallenberg12, Ulrich Specks13 and John H. Stone4, 1Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, 2Immune Tolerance Network, Bethesda, MD, 3Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, 4Rheumatology, Massachusetts General Hospital, Boston, MA, 5Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, 6Rheumatology, Boston University, Boston, MA, 7Rheumatology and Immunology, Duke University, Durham, NC, 8Rheumatology, Hospital for Special Surgery, New York, NY, 9Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, 10Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, 11Rheumatic & Immunologic Dis, Cleveland Clinic Foundation, Cleveland, OH, 12Rheumatology and Clinical Immunology, University of Groningen, Groningen, Netherlands, 13Frederichs Dr NW, Mayo Clinic, Rochester, MN

    Background/Purpose We explored the utility of peripheral CD19+ CD5+ B-cells (CD5+ B-cells) as biomarkers in ANCA-associated vasculitis (AAV)   Methods CD5+ B-cells were measured longitudinally by…
  • Abstract Number: 1308 • 2014 ACR/ARHP Annual Meeting

    Antinucleosome Antibodies As Potential Diagnostic and Prognostic Biomarkers in Childhood Onset Systemic Lupus Erythematosus

    Thaschawee Arkachaisri1, Joo Guan Yeo2, Justin Hung Tiong Tan3, Sook Fun Hoh4, Lena Das3 and Jing Yao Leong2, 1Rheumatology & Immunology, KK Women's and Children's Hospital, Singapore, Singapore, 2Children Intensive Care Unit (CICU), KK Women's and Children's Hospital, Singapore, Singapore, 3Rheumatology and Immunology, KK Women's and Children's Hospital, Singapore, Singapore, 4Nursing, KK Women's and Children's Hospital, Singapore, Singapore

    Background/Purpose: The role of antinucleosome antibodies (ANuA) in the immunopathogenesis of SLE is evident. ANuA was shown to be a good, if not better than…
  • Abstract Number: 754 • 2014 ACR/ARHP Annual Meeting

    The Global miRNA Whole Blood Profile in Systemic Sclerosis and Its Correlation with Serum Cytokine Levels

    Gloria Salazar1, Maureen Mayes2, John Hagan3, Minghua Wu1, John D. Reveille4,5 and Shervin Assassi1, 1Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, 2Internal Medicine/Rheumatology, University of TX Health Science Center -Houston, Houston, TX, 3Neurosurgery, University of Texas at Houston, Houston, TX, 4Internal Medicine/Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, 5Internal Medicine/Rheumatology, Univ of Texas Health Science Center at Houston, Houston, TX

    The Global miRNA Whole Blood Profile in Systemic Sclerosis and its Correlation with Serum Cytokine LevelsBackground/Purpose: Several studies have implicated miRNAs in the pathogenesis of…
  • Abstract Number: 376 • 2014 ACR/ARHP Annual Meeting

    Using the Multi-Biomarker Disease Activity Score As a Complementary Inclusion Criterion for Clinical Trials in Rheumatoid Arthritis May Enhance Recruitment

    Ronald F. van Vollenhoven1, Rebecca J. Bolce2, Karen Hambardzumyan3, Saedis Saevarsdottir4, Kristina Forslind4, Ingemar Petersson5, Eric H. Sasso2, CC Hwang6, Oscar Segurado2 and Pierre Geborek7, 1Unit for clinical therapy research (ClinTrid), Karolinska Institute, Stockholm, Sweden, 2Crescendo Bioscience Inc., South San Francisco, CA, 3ClinTRID, the Karolinska Institute, Stockholm, Sweden, 4Department of Medicine, Karolinska Institute, Stockholm, Sweden, 5Lund University, Department of Orthopedics, Clinical Sciences Lund, Lund, Sweden, 6Biostatistics, Crescendo Bioscience Inc., South San Francisco, CA, 7Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden

    Background/Purpose Clinical trials in rheumatoid arthritis (RA) often require elevated C-reactive protein (CRP) as an inclusion criterion, which may limit recruitment by excluding some patients…
  • Abstract Number: 2787 • 2014 ACR/ARHP Annual Meeting

    Identification of Urinary Biomarkers for Lupus Nephritis

    Carolina Landolt-Marticorena1, Stephenie Prokopec2, Heather Reich3, James Scholey4, Carmen Avila-Casado5, Paul R. Fortin6, Paul Boutros2 and Joan Wither7, 1Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, 2Ontario Institute for Cancer Research, Toronto, ON, Canada, 3Nephrology, University Health Network, Toronto, ON, Canada, 4Department of Medicine, The Toronto Western Hospital, Toronto, ON, Canada, 5Pathology, University Health Network, Toronto, ON, Canada, 6Rheumatology, Laval University, Division of Rheumatology, Centre de Recherche du CHU de Québec and Department of Medicine, Quebec City, QC, Canada, 7Immunology, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Lupus nephritis (LN) is a major determinant of morbidity and mortality in Systemic Lupus Erythematosus (SLE).  Variability in clinical course, underlying renal injury, and…
  • Abstract Number: 1730 • 2014 ACR/ARHP Annual Meeting

    Identification of Novel Scleroderma –associated Antigens and Development of an Autoantibody Assay Panel Enabling Their Subsequent Validation

    Hans-Dieter Zucht1, Petra Budde1, Peter Schulz-Knappe1, Nicolas Hunzelmann2, Karsten Conrad3 and Prof. Dr. Matthias Schneider4, 1Protagen AG, Dortmund, Germany, 2Department of Dermatology, University of Cologne, Cologne, Germany, 3Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, 4Department of Rheumatology, Univ. Duesseldorf, Duesseldorf, Germany

    Background/Purpose: Scleroderma (systemic sclerosis or SSc) has a highly variable clinical presentation and course resulting in difficulties for disease management. When SSc is suspected, autoantibodies…
  • Abstract Number: 1293 • 2014 ACR/ARHP Annual Meeting

    Identification of an Inflammation-Driven Phenotype of Osteoarthritis By Quantification of Synovial Inflammation Ex Vivo and in Serum from Patients

    Cecilie F. Kjelgaard-Petersen1, Anne Sofie Siebuhr2, Kristian Kjaer Petersen3, Lars Arendt-Nielsen4, Thomas Eskehave5, Hans Christian Hoeck5, Ole Simonsen6, Thorbjørn Christiansen7, Line Lindhardt Egsgaard8, Morten A. Karsdal9 and Anne C. Bay-Jensen1, 1Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, 2Rheumatology, Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, 3Department of Health Science and Technology, Faculty of Medicine, Aalborg University, Denmark, Center for Sensory-Motor Interaction, Aalborg, Denmark, 4Department of Health Science and Technology, Faculty of Medicine, Aalborg University, Center for Sensory-Motor Interaction, Aalborg, Denmark, 5Center for Clinical and Basic Research (CCBR), Aalborg, Denmark, 6Frederikshavn Hospital, Frederikshavn, Denmark, 7Orthopaedic Surgery Unit, Gentofte University Hospital, Gentofte, Denmark, 8Center for Sensory-Motor Interaction (SMI), Aalborg University, Aalborg, Denmark, 9Research & Development, Nordic Bioscience, Biomarkers and Research, Herlev, Denmark

    Background/Purpose Osteoarthritis (OA) is a multifaceted degenerative joint disease, where inflammation of the synovial membrane leads to accelerated joint destruction, resulting in elevated release of…
  • Abstract Number: 750 • 2014 ACR/ARHP Annual Meeting

    Molecular Characterization of Systemic Sclerosis Esophageal Pathology Identifies Inflammatory and Proliferative Signatures with Few Fibrotic Markers

    Jaclyn Taroni1, Viktor Martyanov2, Chiang-Ching Huang3, J. Matthew Mahoney4, Ikuo Hirano5, Tammara A. Wood2, Brandon Shetuni6, Guang-Yu Yang6, Darren Brenner5, Barbara Jung7, Swati Bhattacharyya8, Orit Almagor9, Jungwha Lee10, Arlene Sirajuddin11, Rowland W. Chang12, John Varga13, Michael Whitfield14 and Monique Hinchcliff15, 1Genetics, Giesel School of Medicine at Dartmouth, Hanover, NH, 2Department of Genetics, Geisel School of Medicine at Dartmouth, Hanover, NH, 3Zilber School of Public Health, University of Wisconsin, Milwaukee, Milwaukee, WI, 4Department of Neurological Sciences, College of Medicine, University of Vermont, Burlington, VT, 5Department of Medicine, Division of Gastroenterology, Northwestern University Feinberg School of Medicine, Chicago, IL, 6Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, 7Department of Medicine, Division of Gastroenterology, University of Illinois at Chicago, Chicago, IL, 8Medicine/Rheumatology, Northwestern University, Feinberg School of Medicine, Chicago, IL, 9Northwestern University, Chicago, IL, 10Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, 11Department of Radiology, Northwestern University Feinberg School of Medicine, Chicago, IL, 12Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, 13Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, 14Geisel School of Medicine at Dartmouth, Hanover, NH, 15Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL

    Background/Purpose: Esophageal involvement in patients with systemic sclerosis (SSc) is common, but tissue-specific pathological mechanisms are poorly understood. Esophageal muscle atrophy without concomitant fibrosis is…
  • Abstract Number: 350 • 2014 ACR/ARHP Annual Meeting

    Rho-Associated Protein Kinase (ROCK) Activity Is Elevated in Rheumatoid Arthritis (RA) Patients and May be Responsive to RA Therapies

    Reena Khianey1, Cristina Rozo2, Sanjay Gupta3, Vivian P. Bykerk1, Susan M. Goodman1 and Alessandra B. Pernis4, 1Rheumatology, Hospital for Special Surgery, New York, NY, 2535 East 70th Street, Hospital for Special Surgery, New York, NY, 3Hospital for Special Surgery, New York, NY, 4Research, Hospital for Special Surgery, New York, NY

     Background/Purpose: Rho-associated protein kinases (ROCKs) regulate cytoskeletal reorganization and gene expression through protein phosphorylation, and are implicated in the pathogenesis of a wide range of…
  • Abstract Number: 2765 • 2014 ACR/ARHP Annual Meeting

    Putative Blood Biomarkers of Reversible Cerebral Vasoconstriction Syndrome  

    Seby John1, Belinda Willard2, Leonard H. Calabrese2, Ken Uchino3, Tariq Hammad2, Stewart Tepper2, Mark Stillman2 and Rula A Hajj-Ali4, 19500 Euclid Avenue S10-C, Cleveland Clinic Foundation, Cleveland, OH, 2Cleveland Clinic Foundation, Cleveland, OH, 3Neurology, Cleveland Clinic Foundation, Cleveland, OH, 4Rheumatology, Cleveland Clinic Foundation, Cleveland, OH

     Putative blood biomarkers of Reversible Cerebral Vasoconstriction Syndrome Background/Purpose The pathophysiology and molecular mechanisms of Reversible Cerebral Vasoconstriction Syndrome (RCVS) are unknown. Objective of the…
  • Abstract Number: 1699 • 2014 ACR/ARHP Annual Meeting

    Endothelial and Platelet Microparticles As Potential Novel Biomarkers of Peripheral Microvascular Dysfunction in Systemic Sclerosis and Primary Raynaud’s Phenomenon

    John D. Pauling1,2, Daniel Moreno-Martinez3, Fiona Wilkinson4, Ben Parker5,6, Jacqueline A. Shipley1, Darren Hart1, Neil J McHugh1,2 and Yvonne Alexander3, 1Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 2Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, 3Healthcare Science Research Institute, Manchester Metropolitan University, Manchester, United Kingdom, 4School of Healthcare Science, Manchester Metropolitan University, Manchester, United Kingdom, 5Institute of Inflammation and Repair School of Translation Medicine The University of Manchester, Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, 6Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom

    Background/Purpose Microparticles (MPs) are membrane-bound vesicles derived from vascular and intravascular cells such as endothelial cells (EMPs) and platelets (PMPs). MPs form during cell activation…
  • Abstract Number: 1289 • 2014 ACR/ARHP Annual Meeting

    Classification of Osteoarthritis Phenotypes By Metabolomics Analysis

    Weidong Zhang1, Sergei Likhodii2, Yuhua Zhang1, Erfan Aref-Eshghi1, Patricia E. Harper1, Edward Randell2, Roger Green1, Glynn Martin3, Andrew Furey3, Guang Sun4, Proton Rahman5,6 and Guangju Zhai1, 1Discipline of Genetics, Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, 2Department of Laboratory Medicine, Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, 3Department of Surgery, Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, 4Discipline of Medicine, Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, 5Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, 6Rheumatology, St. Claires Mercy Hospital, St. Johns, NF, Canada

    Background/Purpose: Osteoarthritis (OA) is a group of heterogeneous conditions consisting of different subgroups or phenotypes that continuously evolve, eventually leading to common clinical manifestations. Identifying…
  • Abstract Number: 738 • 2014 ACR/ARHP Annual Meeting

    Troponin T as a Diagnostic and Prognostic Biomarker of Primary Cardiac Involvement in Systemic Sclerosis

    Silvia Laura Bosello, Giacomo De Luca, Federico Parisi, Giorgia Berardi, Manuela Rucco, Giovanni Canestrari and Gianfranco Ferraccioli, Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy

    Background/Purpose .Heart involvement is common in Systemic Sclerosis (SSc), even if often clinically silent, and represents one of the leading cause of death in these…
  • « Previous Page
  • 1
  • …
  • 82
  • 83
  • 84
  • 85
  • 86
  • …
  • 96
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology